Recent events
Recent events tied to this brand in public sources.
Back to profile9 entries
2022
Biocon announces Biocon Biologics–Covidshield Technologies merger
Biocon announced that its material subsidiary Biocon Biologics Ltd would merge with Serum Institute of India's wholly owned subsidiary Covidshield Technologies Pvt Ltd, subject to requisite approvals. Biocon Biologics will issue and allot 15% equity shares to Serum on a fully diluted basis.
2021
Biocon and Tabuk announce Middle East commercialisation partnership
Biocon announced a partnership with Tabuk Pharmaceuticals to commercialise selected speciality products in the Middle East. Biocon will develop and manufacture the products, while Tabuk will hold marketing authorisations and register, import and promote them.
2021
Biocon launches generic Everolimus tablets in the US
Biocon announced the US launch of generic Everolimus tablets in four strengths: 2.5 mg, 5 mg, 7.5 mg and 10 mg. The 10 mg tablet was described as a day-one generic launch.
2021
Biocon Pharma and Libbs partner on generic drug formulations in Brazil
Biocon Limited announced that its unit Biocon Pharma had tied up with Brazil-based Libbs Farmaceutica to launch generic drug formulations in Brazil, subject to approval from health regulator ANVISA.
2021
Biocon launches generic drugs in Brazil
Biocon launched its generic drugs in Brazil, entering the Latin American market with generic formulations through an arrangement with Libbs Farmaceutica.
2020
Biocon appoints Anupam Jindal as CFO
Biocon Ltd appointed Anupam Jindal as its new Chief Financial Officer and a member of its executive leadership team. He will take over from interim CFO Indranil Sen, who will continue as Vice-President for Finance.
2020
Biocon Biologics India receives EU GMP certification
Biocon announced that its subsidiary Biocon Biologics India received an EMA Certificate of GMP compliance for multiple biologics drug substance and drug product manufacturing facilities at Biocon Park, Bengaluru.
2020
Biocon Biologics appoints M B Chinappa as CFO
Biocon Ltd appointed M B Chinappa as Chief Financial Officer of its subsidiary Biocon Biologics India Ltd.
2019
Biocon Biologics acquires Pfizer Healthcare India research facility assets
Biocon said its subsidiary Biocon Biologics acquired R&D capital assets for a 60,000-square-foot research facility at Ticel Bio Park in Chennai from Pfizer Healthcare India. The financial terms were not disclosed.